Laurus Labs's book value per share for the quarter that ended in Mar. 2024 was ₹76.25.
During the past 12 months, Laurus Labs's average Book Value Per Share Growth Rate was 1.70% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 16.40% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 23.90% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 22.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 11 years, the highest 3-Year average Book Value Per Share Growth Rate of Laurus Labs was 41.80% per year. The lowest was 9.60% per year. And the median was 19.95% per year.
Laurus Labs's current price is ₹438.15. Its book value per share for the quarter that ended in Mar. 2024 was ₹76.25. Hence, today's PB Ratio of Laurus Labs is 5.75.
During the past 11 years, the highest P/B Ratio of Laurus Labs was 13.44. The lowest was 2.07. And the median was 4.55.
Laurus Labs Book Value per Share Historical Data
The historical data trend for Laurus Labs's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Laurus Labs's Book Value per Share
For the Drug Manufacturers - Specialty & Generic subindustry, Laurus Labs's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Laurus Labs's PB Ratio Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Laurus Labs's PB Ratio distribution charts can be found below:
* The bar in red indicates where Laurus Labs's PB Ratio falls into.
Laurus Labs Book Value per Share Calculation
Laurus Labs's Book Value Per Share for the fiscal year that ended in Mar. 2024 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.
Laurus Labs (BOM:540222) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
Laurus Labs Book Value per Share Related Terms
Thank you for viewing the detailed overview of Laurus Labs's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Laurus Labs Ltd is a pharmaceutical company based in India. It provides active pharmaceuticals ingredients (API) including intermediates, Generic Finished dosage forms (FDF) and Contract Research services. The entity develops APIs and intermediates for select, high-growth antiretrovirals, Hepatitis C and Oncology. It also manufactures APIs in other therapeutic areas, such as anti-asthma, ophthalmology, anti-diabetics, cardiovascular, proton pump inhibitors, among others. The company has its business presence in India and Outside India of which it derives a majority of revenue from Outside India. It generates revenue from the sale of API, Intermediates and Formulations, Contract research services and others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BOM:540222 has been successfully added to your 